Pharmaceutical composition of fused aminodihydrothiazine derivative
AssigneeEisai R&D Management Co., Ltd.
InventorsYasuhiro Zaima, Kazuo Kazama, Shuntaro Arase, Kentaro Nagane, Kanta Horie, Yosuke Ueki
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
Claims4
A pharmaceutical composition comprising a compound represented by formula (1):
- or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and
- a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
A pharmaceutical composition comprising a compound represented by formula (1):
- or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and
- means that does not cause a substantial change in the dissolution profile even after storage for a certain period of time.
Dependencies are inferred from the claim text.